Language proficiency and biologics access: a population study of psoriasis patients in the United States

Chat, Vipawee S; Hekmatjah, Joshua; Sierro, Tiffany; Kassardjian, A.; Read, Charlotte; Armstrong, April W.

doi:10.1080/09546634.2020.1820936

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hispanic patients may also utilize dermatology clinics less than non-Hispanic White patients due to language barriers. For example, prior work by our team found that language barriers are strongly associated with decreased access to care, including access to biologic medications for psoriasis [25]. Therefore, for Spanish-only-speaking patients, having a Spanish-speaking healthcare provider may substantially augment the visit experience and possibly lead to better patient outcomes.…”

Section: Discussionmentioning

confidence: 96%

Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White Patients

Zagona-Prizio¹,

Khan²,

Yee³

et al. 2023

DOJ

View full text Add to dashboard Cite

Percentages are rounded. a Education level is stratified into three groups for participants who received a high school education or below (high school), some college or a college degree (college), and a graduate level education and above (graduate). b Income calculated as a percentage of the poverty line, grouped into the categories of low income (<200% of the poverty line), middle income (200-399%), and high income (>399%).

show abstract

Section: Discussionmentioning

confidence: 96%

Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White Patients

Zagona-Prizio¹,

Khan²,

Yee³

et al. 2023

DOJ

View full text Add to dashboard Cite

show abstract

“…This has been shown for South Asians [8], Blacks [9], Latinos [10] and East European migrants [8]. However, there have been no studies on this issue in relation to rheumatoid arthritis or psoriasis, although an American report has linked lack of proficiency in English to a 60-fold reduction in access to biologic therapy [11]. This finding is consistent with that from Miami where an underserved community did not receive biologic therapy for inflammatory bowel disease because of system failures within the healthcare system [12].…”

Section: Discussionmentioning

confidence: 99%

Is there disparate provision of biologic therapies for chronic inflammatory conditions in New Zealand?

Farrukh¹,

JF²

2022

J Clin Images Med Case Rep

View full text Add to dashboard Cite

Biologic therapy is approved for the treatment of rheumatoid arthritis, inflammatory bowel disease and psoriasis in New Zealand. In order to qualify for subsidy for infliximab or adalimumab, treatment must be initiated by a relevant specialist. However, there is a clear role for family practitioners in ensuring that appropriate patients are offered these treatments regardless of ethnicity or levels of social deprivation. This issue was highlighted by the work of Mc Creanor and Nairn [1], who identified a tendency amongst non-Maori family physicians to attribute differences in health disparities as being due to the community itself. Such attitudes towards minority communities are widespread throughout the world and were most recently reported in the UK in the Report by the Commission on Race and Ethnic Disparities [2]. The potential for a significant role in the delivery of equitable care to Maoris and Pacific Islanders, following the passage of the Health Practitioners Competence Assurance Act, was outlined by Bacal et al [3]. General practitioners role in appropriate communication about new treatments was emphasised together with the fact that they were seen as trustworthy. Such relationships are often not established with specialist hospital-based practitioners, who may be seen as distant and disinterested. However, a study of arthritis in New Zealand has shown that despite the disease having a higher prevalence in indigenous peoples, fewer referrals were made by family doctors to specialists [4]. Consequently, their access to expensive treatments, such as biologic therapies was limited. In this small study, access to biologic therapy across various communities was considered.

show abstract

Disparities in Care for Psoriasis

Drozdowski,

Jain,

Gronbeck

et al. 2024

Dermatologic Clinics

View full text Add to dashboard Cite

Language proficiency and biologics access: a population study of psoriasis patients in the United States

Cited by 5 publications

References 21 publications

Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White Patients

Differences in accessing dermatology offices, primary care offices, and emergency departments between Hispanics and Non-Hispanic White Patients

Is there disparate provision of biologic therapies for chronic inflammatory conditions in New Zealand?

Disparities in Care for Psoriasis

Contact Info

Product

Resources

About